Semaglutide, the diabetes drug at the center of a global boom in weight-loss treatments, has entered the Moroccan market through a partnership between Danish pharmaceutical company Novo Nordisk and ...

Walmart is joining Costco, Sam’s Club, and CVS in offering cheaper prices for customers paying out of pocket for Zepbound, ...

CHICAGO -- Novel orexin receptor 2 agonist oveporexton normalized wakefulness for most people with narcolepsy type 1 in two ...

In a small study, patients who have successfully lost weight with weekly GLP-1 treatment maintain their weight loss and ...

Narcolepsy type 1 is a chronic, rare neurological disease caused by the loss of orexin neurons in the brain. Orexin is a ...

China's Innovent Biologics saidon Monday its GLP-1 injection led to more weight loss and better control of blood sugar in ...

SAN FRANCISCO -- Two studies demonstrated the benefits of treating juvenile myasthenia gravis (MG) with newer drugs.

Terns Pharmaceuticals halts its TERN-601 obesity program due to insufficient efficacy and safety concerns. Click here to read ...

Early data from the ADAPT JR trial suggest efgartigimod may benefit adolescents with generalized myasthenia gravis, a rare ...

A once-daily oral quadruple receptor agonist induced up to 13.8% weight loss at 13 weeks among adults with overweight or ...

Second-generation anti-VEGF agents, like aflibercept 8 mg and faricimab, show improved efficacy and treatment durability in ...

Zocilurtatug pelitecan shows promising results as a DLL3-targeted therapy for small cell lung cancer, with high response rates and ongoing trials.